Peter Gilbert

发表

Weighted Likelihood Method for Grouped Survival Data in Case–Cohort Studies with Application to HIV Vaccine Trials

Bin Nan, B. Nan, P. Gilbert, 2008, Biometrics.

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Jaranit Kaewkungwal, Joseph Chiu, Nelson L Michael, 2012, The Lancet. Infectious diseases.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Morgane Rolland, P. Gilbert, Peter Gilbert, 2012, AIDS research and human retroviruses.

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

Hasan Ahmed, Hongmei Gao, Jaranit Kaewkungwal, 2012, The Journal of infectious diseases.

HIV-1 Vaccines and Adaptive Trial Designs

Louis J. Picker, Gary J. Nabel, Lawrence Corey, 2011, Science Translational Medicine.

COMPASS identifies T-cell subsets correlated with clinical outcomes

Greg Finak, Raphael Gottardo, Jaranit Kaewkungwal, 2015, Nature Biotechnology.

Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

Xuesong Yu, Gary Li, Hongmei Gao, 2012, Journal of immunological methods.

Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines

Lynn Morris, Christos J. Petropoulos, John R. Mascola, 2005, Journal of Virology.

Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

Xiping Wei, Feng Gao, John R. Mascola, 2005, Journal of Virology.

Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana

Max Essex, P. Gilbert, D. Bangsberg, 2003, Journal of acquired immune deficiency syndromes.

Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials

Julian Wolfson, P. Gilbert, J. Wolfson, 2010, Biometrics.

HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the “Test-and-Treat” Approach to Reduce HIV Transmission

Sikhulile Moyo, Victor DeGruttola, Shahin Lockman, 2010, PloS one.

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

Raphael Gottardo, S. Gnanakaran, Hongmei Gao, 2013, PloS one.

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load

Tomer Hertz, Julian Wolfson, Holly Janes, 2012, PloS one.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Punnee Pitisuttithum, P. Gilbert, J. Tappero, 2006, The Journal of infectious diseases.